IN THE CLAIMS

Please amend claims 32-34 and 36, as shown below. Please cancel claims 7, 9, 12, 15-31, and 35 without prejudice. Please enter new claims 39-48. The following is the listing of the claims replacing all previous listings.

1-31. (Canceled).

32. (Currently amended) A method ~~for~~ of removing ~~carbonyl compounds~~ glyoxal and/or methylglyoxal from one or more body fluids selected from the group consisting of blood, blood plasma and peritoneal dialysate, the method comprising contacting ~~the carrier of claim 23~~ a carrier on which one or more biguanide agents have been immobilized with ~~one or more~~ said body fluids ~~selected from blood, blood plasma and peritoneal dialysate~~, thereby removing glyoxal and/or methylglyoxal in said body fluids, wherein the biguanide agents are selected from the group consisting of phenformin, buformin, and pharmacologically acceptable salts thereof.

33. (Currently amended) The method of claim 32, wherein ~~the removal~~ removing of ~~the carbonyl compounds~~ glyoxal and/or methylglyoxal is carried out during *in vivo* or *ex vivo* blood purification.

34. (Currently amended) A method ~~for~~ of removing ~~carbonyl compounds~~ glyoxal and/or methylglyoxal from one or more body fluids selected from the group consisting of blood, blood plasma and peritoneal dialysate, the method comprising contacting one or more biguanide ~~agent~~ agents with ~~one or more~~ said body ~~fluid~~ fluids ~~selected from blood, blood plasma and peritoneal dialysate~~, thereby glyoxal and/or methylglyoxal in said body fluids are removed, wherein the biguanide agents are selected from the group consisting of phenformin, buformin, and pharmacologically acceptable salts thereof.

35. (Canceled).

36. (Currently amended) The method of claim 34, wherein ~~the removal~~ removing of ~~the carbonyl compounds~~ glyoxal and/or methylglyoxal is carried out during *in vivo* or *ex vivo* blood purification.

37. (Previously presented) The method of claim 34, wherein the biguanide agent is orally administered.

38. (Previously presented) The method of claim 34, wherein the biguanide agent is administered by injection.

39. (New) The method of claim 32, wherein the carrier is one or more materials selected from the group consisting of synthetic or naturally-occurring organic macro-molecular compounds, inorganic material and materials coated with polysaccharide(s) and synthetic polymer(s) thereof.

40. (New) The method of claim 32, wherein the carrier is an inorganic material.

41. (New) The method of claim 40, wherein the inorganic materials are selected from the group consisting of glass beads, silica gel, alumina and activated charcoal.

42. (New) The method of claim 40, wherein the carrier is a synthetic organic macro-molecular compound.

43. (New) The method of claim 32, wherein the carrier is selected from the group consisting of a membranous, a fibrous, a granular-shaped, a hollow fiber-like, a non-woven fabric-like, a porous, and a honeycomb-shaped carrier.

44. (New) The method of claim 32, wherein the carrier has a body fluid contact area that can be controlled by altering one or more parameters selected from the group consisting of thickness, surface area, diameter, length, shape and size of the carrier.

45. (New) The method of claim 32, wherein the biguanide agent is immobilized on the carrier by one or more reactions selected from the group consisting of physical adsorption, a specific biochemical binding reaction, ion binding, covalent bonding and grafting.

46. (New) The method of claim 32, wherein the carrier is a hemodialysis membrane.

47. (New) The method of claim 33, wherein the blood purification comprises one or more steps selected from the group consisting of blood filtration, blood filtration dialysis, blood adsorption, and blood plasma separation.

48. (New) The method of claim 36, wherein the blood purification comprises one or more steps selected from the group consisting of blood filtration, blood filtration dialysis, blood adsorption, and blood plasma separation.